Malaysia Atopic Dermatitis Therapeutics Market Report 2022 to 2030

Malaysia Atopic Dermatitis Therapeutics Market Analysis

$ 3999

The Malaysia Atopic Dermatitis Therapeutics Market was valued at US $20 Mn in 2022, and is predicted to grow at (CAGR) of 9% from 2023 to 2030, to US $39 Mn by 2030. The key drivers of this industry include increasing disease burden of Atopic Dermatitis (AD), supportive government policies, and technological advancements. The industry is primarily dominated by players such as Meda, Ivax, Pharmaniaga, Marufa, Sanofi, Novartis, Johnson & Johnson, and AbbVie among others.

ID: IN10MYPH435 CATEGORY: Pharmaceuticals GEOGRAPHY: Malaysia AUTHOR: Riddhi Solanki

Buy Now

Malaysia Atopic Dermatitis Therapeutics Market Analysis: Executive Summary

The Malaysia Atopic Dermatitis Therapeutics Market is at around US $20 Mn in 2022 and is projected to reach US $39 Mn in 2030, exhibiting a CAGR of 9% during the forecast period.

Atopic dermatitis (AD), commonly referred to as eczema, is a chronic inflammatory skin condition characterized by redness, itching, and inflammation. It often presents as localized patches on different areas of the body and can be aggravated by factors such as dry skin, stress, and exposure to specific irritants or allergens. Key symptoms include intense itching, redness, dryness, and the development of small, fluid-filled blisters that may release fluid and form crusts. Treatment typically involves a comprehensive approach, incorporating the use of emollients for skin moisturization, topical corticosteroids to alleviate inflammation, and, in severe cases, systemic immunosuppressants. Various pharmaceutical companies produce medications for atopic dermatitis, with noteworthy examples including Dupixent (Dupilumab) from Regeneron Pharmaceuticals and Sanofi, Eucrisa (Crisaborole) from Pfizer, and Elidel (Pimecrolimus) from Novartis.

The estimated overall prevalence of atopic dermatitis (AD) in Malaysia is approximately 13.4%. The market is being driven by significant factors, such as the increasing prevalence of AD supportive government policies and technological advancements in the therapeutics market. However, conditions such as poor reimbursement policies, a lack of human resources, and local competition limit the growth and potential of the market.

Market Dynamics

Market Growth Drivers

Increasing AD burden: The overall prevalence of AD is estimated to be around 13.4% in Malaysia. The burden of environmental factors such as pollution and dietary changes related to urbanization is connected to a higher prevalence of AD. Malaysia's diverse population, consisting of various ethnicities, has an increased genetic susceptibility to AD.

Supportive government policies: Initiatives such as Skim Sihat Selangor and Bantuan Sara Hidup, implemented by the government, aim to enhance healthcare accessibility and make medications more affordable, particularly for low-income families. The rise in private health insurance coverage offers financial protection for the costs associated with AD treatment.

Technological advancements: The introduction of specific biologic therapies, such as dupilumab, brings about substantial enhancements in the management of moderate to severe AD. Progress in genetic testing and the identification of biomarkers lays the foundation for personalized treatment strategies and better outcomes.

Market Restraints

Poor reimbursement policies: While the Malaysian healthcare system provides some public insurance coverage for specific treatments, it may not be all-encompassing. Insufficient reimbursement acts as a deterrent for patients to seek regular care, thus restricting market growth.

Lack of professionals: A scarcity of well-trained dermatologists and healthcare professionals proficient in handling atopic dermatitis can restrict the quality of care and adherence to treatment plans.

Local competition: The availability of diverse generic and branded topical steroids and emollients triggers price competition, constraining profit margins for pharmaceutical companies and hampering innovation in the development of new therapeutic options.

Healthcare Policies and Regulatory Landscape

Malaysia's healthcare regulatory landscape is governed by the Malaysian Ministry of Health (MOH) and its regulatory agency, the National Pharmaceutical Regulatory Agency (NPRA). The NPRA is responsible for ensuring the safety, efficacy, and quality of pharmaceuticals, cosmetics, and medicinal products in Malaysia.

Companies seeking to introduce new drugs to the Malaysian market must go through the NPRA's regulatory processes, which include rigorous evaluation and approval procedures to ensure compliance with local standards and regulations. The registration and licensing of pharmaceutical products involve the submission of comprehensive documentation, including data on product safety, efficacy, and quality, to the NPRA.

For new entrants in the Malaysian healthcare market, navigating the regulatory environment requires a thorough understanding of the country's regulatory requirements and standards. The NPRA plays a pivotal role in granting licenses for pharmaceutical products, and companies must adhere to the established procedures to obtain approval. The regulatory environment emphasizes the importance of compliance with safety and quality standards, making it essential for new entrants to invest in regulatory affairs and quality assurance.

Competitive Landscape

Key Players

Sanofi
GlaxoSmithKline
Pfizer
AbbVie
Novartis
Johnson & Johnson
Meda Pharmaceuticals
Marufa Sdn Bhd
Pharmaniaga Berhad
Ivax Pharmaceuticals

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Malaysia Atopic Dermatitis Therapeutics Market Segmentation

By Drug Class

Corticosteroids
Calcineurin Inhibitors
Immunosuppressants
Biologic Therapy
PDE-4 Inhibitor
Antibiotics
Antihistamines
Emollients

By Route of Administration

Topic
Oral
Injectable

By Severity type

Mild
Moderate
Severe

By Age Group

18 years and below
19 years and above

By Distribution channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Dermatology Clinics
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.